Specialty Pharmacy

Fiona Smythe, vice president of strategy at mscripts, discusses developing trends in mobile health care applications.

Restoration of miR-29 in cancer stromal cells helped decrease cancer growth.

Tumor suppressing molecule that prevents growth could lead to personalized therapy.

Treatment could make existing cancer drugs more effective.

Drug decreases enthesitis and dactylitis by blocking the production of cytokines that promote inflammation.

Gilead Sciences is seeking FDA approval for its third tenofovir alafenamide-based HIV treatment.

Hydrogel prevents drugs from prematurely leaving the body.

Top stories of the week on Specialty Pharmacy Times from June 29 through July 3.

Lung function and health status decreases across all levels of severity.

The impact of products such as orange juice on melanoma.

Patients face significant financial burdens from treatment.

CEO of Avella Specialty Pharmacy Rebecca M. Shanahan, Esq., discusses how specialty pharmacies can best manage the rising cost of specialty drugs to improve outcomes for patients.

Drug targets the cause of the disease in people who have two copies of a specific mutation.

Coverage restrictions on wrong side of Medicaid law requiring states to cover drugs consistent with FDA labels.

Ocrelizumab may shift MS treatment paradigm.

Study finds current efforts are not enough to decrease the spread of infection.

A federal judge has entered a consent decree of permanent injunction against a manufacturing company for marketing unapproved and misbranded prescription drugs.

There are currently more than 600 trials of biosimilars ongoing.

Monitoring activity in a protein could be crucial to detecting cancer early on.

Cancer treatment is more closely involving community and specialty pharmacies, as many patients are being treated with oral, subcutaneous, and intravenous (IV) agents in the comfort of their own homes.

Patients with genotype 1b hepatitis C achieve sustained virologic response after 12 weeks.

Hormones that reduce side effects may stimulate growth of cells resistant to therapy.

Combination of immunotherapy and epigenetics put patients into remission, even after failing the standard treatment.

Abstracts are due by September 15, 2015.

Track-and-trace requirements of the Drug Quality and Security Act (DQSA) will take effect tomorrow, but the FDA will not enforce the product tracing obligations for pharmacies until November.

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses developing trends in the treatment of specialty pharmacy patients.

Productivity and absenteeism improved in patients with chronic inflammatory arthritides.

California's Affordable Care Act health insurance exchange marketplace is the first in the nation to enact a payment cap policy for expensive specialty drugs.

Preventative measures emphasized to reduce transmission of disease.

Top stories of the week on Specialty Pharmacy Times from June 22-26.